Filing Details

Accession Number:
0001209191-12-008147
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-02-07 16:29:32
Reporting Period:
2012-02-06
Filing Date:
2012-02-07
Accepted Time:
2012-02-07 16:29:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1298332 Matthew Emmens C/O Vertex Pharmaceuticals Incorporated
130 Waverly St
Cambridge MA 02139
Executive Chairman No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-02-06 2,500 $36.39 265,101 No 4 S Direct
Common Stock Disposition 2011-02-06 12,900 $37.11 252,201 No 4 S Direct
Common Stock Disposition 2011-02-06 40,600 $38.08 211,601 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Transaction made pursuant to Mr. Emmens' company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $36.39 (range $35.64 to $36.61).
  3. Mr. Emmens undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $37.11 (range $36.68 to $37.67).
  5. Open market sales reported on this line occurred at a weighted average price of $38.08 (range $37.70 to $38.33).